BAFF and APRIL Immunomodulatory Proteins (US12612447B2)
Summary
The USPTO granted Patent US12612447B2 to Alpine Immune Sciences, Inc. on April 28, 2026, covering BAFF and APRIL immunomodulatory proteins including TACI-Fc fusion proteins for treating immunological diseases. The patent includes 57 claims and lists six inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, and Stanford L. Peng. The filing date was March 17, 2023.
“The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
The USPTO issued Patent US12612447B2 to Alpine Immune Sciences, Inc. covering immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The patent claims variant domains of Transmembrane Activator and CAML Interactor (TACI), including TACI-Fc fusion proteins, as well as nucleic acid molecules encoding these proteins and methods of using them for treating immunological diseases.
This patent grant provides Alpine Immune Sciences with enforceable intellectual property rights in the United States. No compliance obligations are imposed on other parties. Pharmaceutical and biotechnology companies developing BAFF/APRIL pathway inhibitors should consider potential freedom-to-operate implications when advancing related programs toward clinical development.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
Grant US12612447B2 Kind: B2 Apr 28, 2026
Assignee
ALPINE IMMUNE SCIENCES, INC.
Inventors
Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
Abstract
Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
CPC Classifications
C07K 14/70578 C07K 2319/31 C07K 2319/30 A61K 38/1774
Filing Date
2023-03-17
Application No.
18186098
Claims
57
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.